a NEW cardiovascular disease (CVD) quality improvement program has been launched to support healthcare providers in managing patients' cholesterol more effectively.
The LipidPlan in a Box was developed by Novartis Australia in collaboration with a multidisciplinary team comprising primary care experts, specialists and patient advocacy groups, and aims to enhance the quality of care for patients with atherosclerotic cardiovascular disease.
Pharmacists play a vital and complementary role in cardiovascular risk management alongside other primary health practitioners, and LipidPlan in a Box supports practices in identifying and managing patients who are not at LDL-C target.
Pharmacists are also often the first to notice adherence challenges, side effects or opportunities for therapy optimisation, and are well placed to provide patient education, identify at-risk patients for GP follow-up and support lifestyle interventions.
Assoc Prof Karam Kostner from the University of Queensland and Director of Cardiology at Mater Hospital Brisbane, said that a strong foundation in primary care is essential for reducing the burden of CVD.
"In cardiology, we often see patients who arrive with advanced disease, where earlier intervention could have changed the trajectory of their condition," he said.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 25
